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VOLUME 23 NUMBER 9 SEPTEMBER 2016 nature structural & molecular biology a r t i c l e s 70-and ~80-fold higher for subtypes A and B, respectively) in rhesus macaques 31 , whereas SC-DM induces complete protection against viral challenge in cotton rats and remains primarily in the prefusion state for over 50 days at 4 °C (ref. 32) . Although these antigens show promise, the duration of infant protection achieved by maternal immunization awaits clinical evaluation, and every two-fold increase in immunogenicity would potentially extend protection in infants by an additional month. Because RSV-mediated disease may largely be a consequence of obstruction in small airways, owing to accumulation of sloughed epithelium, mucus, fibrin and inflammatory debris 33 , a major goal in the development of RSV vaccines has been to delay the timing of primary RSV infection until infants are older and their airways are larger.
We therefore sought to optimize the immunogenicity of the firstgeneration RSV antigens. Historically, boosting neutralizing activity in humans with preexisting immunity has been difficult: decades' worth of RSV-vaccine research has previously achieved an increase of only two-to four-fold in RSV-neutralizing titers in healthy adults [34] [35] [36] , and the increase in immunogenicity of pre-F DS-Cav1 over postfusion RSV F was considered to be one of the top scientific breakthroughs of 2013 (ref. 37) . How might the immunogenicity of the first-generation pre-F antigens be increased?
We hypothesized that each cycle of structure-based design might provide clues to optimize immunogenicity and that we could explore these clues iteratively. Here, we describe our efforts to improve the immunogenicity of DS-Cav1 through iterative cycles of structurebased design. In each cycle, we used atomic-level design to engineer variants. We expressed these variants, assessed their antigenic and physical properties, determined their structures, measured the immunogenicity of select variants and statistically analyzed the results. The statistical analyses involved the 'informatics' of design, properties, structure and immunogenicity, which we have previously postulated 31 might provide a direction for improvements in immunogenicity. In total, we performed four cycles of structure-based engineering involving the design, expression and antigenic assessment of hundreds of variants, the crystal structures of six variants and the immunogenicity of 14 variants. The resultant second-generation DS2 antigens had increased antigenic stability and induced significantly higher RSV-neutralizing activity-an achievement critical to extending and improving vaccine-induced immunity against RSV-mediated disease.
RESULTS

Engineering and properties of vaccine-design cycle 1
In the structure-based design of DS-Cav1 (ref. 31) , we previously examined the interplay among design, physical and antigenic properties, atomic-level structure and immunogenicity to understand the relationships among the antigenic and physical properties of the engineered RSV Fs and the elicitation of RSV-protective responses. The correlation between the physical stability of the prefusion-specific site Ø and immunogenicity suggested that further increases in physical stability might increase immunogenicity 31 . We therefore sought ways to increase the physical stability of antigenic site Ø 29 .
Studies with other type 1 fusion proteins have suggested that genetically fusing the two subunits of mature pre-F into a single chain might enhance stability 32, 38, 39 . We therefore engineered DS-Cav1 variants with F 2 genetically fused to F 1 and with both the fusion peptide and the pep27 region deleted 40 (Fig. 1) . In particular, for the C terminus of F 2 (where we engineered the start of the genetic linkage), we chose two positions: residue 97, at the end of the α1 helix, and residue 105, one residue after the last residue of F 2 visible in the electron density of the DS-Cav1 structure (Fig. 1a,b) . For the N terminus of F 1 (where we engineered the end of the genetic linkage), we chose either residue 145, which is just after the fusion peptide, or residue 151, which is a glycine in the α2 helix and might facilitate flexibility (Fig. 1a,b) .
We synthesized 45 constructs with a variety of linkers (Supplementary Table 1 ) and tested their expression in a 96-well-microplate transient-transfection format 31 . Five of these constructs expressed at levels allowing characterization of their antigenic and physical properties ( Tables 1 and 2 ). Of these, sc9 DS-Cav1, comprising a GS linkage between residues 105 and 145, showed four-fold-enhanced expression and recognition by several prefusion-specific antibodies (Fig. 1c) . Notably, the single-chain variants showed altered mobility in size-exclusion chromatography (SEC) (Supplementary Fig. 1 ), and many displayed reduced tolerance to physical extremes ( Table 2) . However, sc9 DS-Cav1 did show an increased ability to retain antigenic site Ø after incubation at 70 °C, as assessed by binding to the site-Ø-specific antibody D25. Specifically, 39% of sc9 DS-Cav1 was antigenically sound whereas site Ø on the parent DS-Cav1 was completely lost after a 1-h incubation at 70 °C ( Table 2) .
Structures, immunogenicities and informatics of cycle 1
To assess the effects of the sc9 alteration on DS-Cav1, we crystallized and determined the structure of sc9 DS-Cav1 at 2.98-Å resolution ( Table 3 ). The structure of sc9 DS-Cav1 was similar to that of the parent DS-Cav1, with an r.m.s. deviation of 0.6 Å for all residues excluding 105-151 (Fig. 1c) . The fusion-peptide deletion did not induce any substantial movements in the neighboring region (Fig. 1d) , where the new connection between residues 105 and 145 showed partially ordered electron density (Fig. 1d) . Thus, the structural effects of fusing F 2 to F 1 and removing the fusion peptide on the structure of DS-Cav1 were minimal and localized almost entirely to the linker region.
To measure the immunogenicity of the various single-chain DS-Cav1 molecules, we intramuscularly immunized CB6F1/J mice with 10 µg RSV F combined with 50 µg polyinosinic-polycytidylic acid adjuvant at weeks 0 and 3 and evaluated the ability of sera from week 5 to prevent RSV infection in HEp-2 cells. Notably all titers elicited by these single-chain antigens were lower than those elicited by DS-Cav1 (Fig. 1e) . Variants sc8 DS-Cav1 and sc11 DS-Cav1 had especially low immunogenicity, whereas sc9 DS-Cav1, the single-chain variant with the highest immunogenicity, had a geometric-mean titer one-third that of DS-Cav1.
The increased physical stability of sc9 DS-Cav1 at 70 °C did not yield an increase in immunogenicity, thus indicating that other factors with more substantial effects on immunogenicity had probably been altered between DS-Cav1 and sc9 DS-Cav1. We analyzed the immunogenicity of the five characterized single-chain DS-Cav1 constructs, sc4, sc8, sc9, sc10 and sc11, in the context of their (i) antigenicities toward site-Ø antibodies (D25, AM22 and 5C4), motavizumab and quaternary-specific antibodies (MPE8 and AM14) and (ii) physical properties, such as elution volume, expression yield and physical stability (as determined by retained D25 reactivity after exposure to various physical extremes) (Fig. 1f) . No single property significantly correlated with immunogenicity. However, we noticed that the property with the largest absolute correlation with immunogenicity was elution volume (anti-correlation, Fig. 1f ) (Pearson correlation r = −0.976, P = 0.0042 for single-chain constructs). Although the relationship between elution volume and immunogenicity probably has an optimum as opposed to monotonically increasing or decreasing, and the number of data points was small, we nevertheless selected sc9 DS-Cav1 for further optimization on the basis of its antigenicity and its also having the highest immunogenicity among the singlechain constructs. npg a r t i c l e s Structure-based optimization for vaccine-design cycle 2 Because differences in the linker between F 2 and F 1 subunits appeared to affect immunogenicity, we further varied this linker and also altered residues in the F 2 α1 helix (Fig. 2a) . We synthesized 45 variants of sc9 DS-Cav1 (Supplementary Table 1 ) and tested their expression in a 96-well-microplate transient-transfection format 31 . Most of these constructs expressed at levels that allowed characterization of their antigenic and physical properties (Tables 1 and 2 and Fig. 2b ). Of these, one construct, sc9-10 DS-Cav1 (which differed from sc9 DS-Cav1 by its lack of residues 104 and 105), had a SEC elution volume similar to that of DS-Cav1 (Fig. 2b) and displayed improved affinity (from 33.1 nM to 6.6 nM) for the prefusion quaternary-specific antibody AM14 ( Table 1) . Constructs sc9-41 and sc9-42 with shortened F 2 linkers did not bind to prefusion-specific antibodies despite containing DS-Cav1 stabilizing mutations, thus indicating that subtle changes in the F 2 -F 1 linker sequence and length can substantially affect antigenicity. sc9-10, compared with sc9, had a similarly improved affinity to antibody AM14, as did sc9-9; however, we did not choose sc9-9 for further improvement because it had a suboptimal SEC profile and was polydisperse, as assessed by dynamic light scattering (DLS).
To provide atomic-level details, we crystallized and determined the structures of the sc9-10, sc9-19 and sc9-24 versions of DS-Cav1 at 3.6-, 2.6-and 2.9-Å resolution, respectively ( Table 3 ). All of these structures were highly similar to that of the parent sc9 DS-Cav1 (Fig. 2c) but had important differences in their F 2 -F 1 linkers, as expected from the sequence changes in this region (Fig. 2d) a r t i c l e s compared with sc9, had improved electron density in the linker region, whereas the sc9-24 electron density was similar to that of sc9.
As before, we measured the immunogenicity of the various single-chain DS-Cav1 molecules by immunizing CB6F1/J mice at weeks 0 and 3. Importantly, the titers of sc9-10 DS-Cav1 at week 5 (geometric mean of 1,988) were statistically indistinguishable from those of DS-Cav1 (Fig. 2e) . Notably, statistical analysis indicated that the quaternary-specific-antibody affinity correlated significantly with improved immunogenicity (P = 0.0083, Fig. 2f ), thus suggesting that decreased protomer flexibility might lead to improved neutralizing The fractional value refers to the D25 reactivity retained after exposure to various physical extremes, compared with the initial D25 binding level, as measured by Octet biolayer interferometry. npg a r t i c l e s titers. For the third cycle of structure-based design, we thus sought to reduce protomer flexibility even further, by introducing interprotomer disulfide linkages.
Structure-based optimization for vaccine-design cycle 3
We analyzed the structure of sc9-10 DS-Cav1 for interprotomer positions where disulfide linkages might be introduced (Fig. 3a) . We synthesized 17 variants of sc9-10 with introduced interprotomer disulfides (Supplementary Table 1 ) and tested their expression in a 96-well-microplate transient-transfection format. Four of these constructs expressed at levels that allowed characterization by reducing and nonreducing SDS-PAGE (Fig. 3b) ; in the absence of reducing agent, all of these constructs ran as disulfide-linked oligomers of >150 kDa without detectable dimer or monomer populations. In the presence of reducing agent, all four ran as monomers of ~60 kDa. The sc9-10 DS-Cav1 A149C Y458C variant expressed at 1 mg/L, the N183GC N428C variant expressed at only ~0.1 mg/L (but showed a typical pre-F structure by negative stain-EM (Fig. 3c) ) and the T100C S362C and T369C T455C variants expressed at quantities too low for characterization. Disulfide bonds also formed, as tested with two-residue variations around the T100C S362C disulfide-bond location (for example, 98C and 361C). Both sc9-10 DS-Cav1 A149C Y458C and N183GC N428C variants showed 6-fold and 19-fold increased physical stability, respectively, over that of DS-Cav1 at 60 °C ( Table 2 Table 2) .
We crystallized and determined the structure of sc9-10 DS-Cav1 A149C Y458C at 2.65-Å resolution ( Table 3 ). The structure of sc9-10 DS-Cav1 A149C Y458C was similar to that of the parent sc9-10 DS-Cav1 (Fig. 3d) . Notably, we observed a strong electron density between residues 149 and 458, which was consistent with the formation of a disulfide bond. Moreover, the overall quaternary structure was maintained between sc9-10 and sc9-10 DS-Cav1 A149C Y458C, with a low r.m.s. deviation for protomer (0.9 Å) and for the entire trimer (1.0 Å).
To measure the immunogenicity of the second-generation DS-Cav1 with interprotomer disulfides (which we named DS2 immunogens, for their second disulfide), we immunized CB6F1/J mice intramuscularly as described for earlier variants (Fig. 3e) . Notably, two DS2 immunogens, sc9-10 DS-Cav1 A149C Y458C and N183GC N428C, showed a significant increase in RSV-neutralizing titer, three-to four-fold higher than that of DS-Cav1. When we statistically analyzed the cumulative data on immunogenicity versus various properties from design cycles 1-3, both quaternary-specific-antibody affinity (P = 0.0016) and physical stability (P = 0.0029) significantly correlated with immunogenicity ( Fig. 3f) , thus indicating the importance of appropriate quaternary organization as well as improved physical stability in the elicitation of RSV-neutralizing antibodies.
Structure-based optimization for vaccine-design cycle 4
The heightened immunogenicity of DS2 immunogens with interprotomer disulfides indicated that interprotomer stabilization might be a general way to increase the elicitation of RSV-protective responses. However, the low expression levels of many of the designed interprotomer variants revealed expression to be a roadblock. For design cycle 4, we therefore strove to combine interprotomer disulfides A149C Y458C and N183GC N428C (Fig. 3) with other mutations that might additionally stabilize the prefusion state or increase expression, including Fig. 3 ) as well as variant strains of RSV such as the Long strain and subtype-B strains such as CH18537 (UniProt P13843) 41 ( Fig. 4 and Supplementary Table 1) . We synthesized 396 constructs and assessed their antigenicities and expression levels in a 96-well-microplate transient-transfection format. Six of these constructs expressed at levels that allowed characterization of their antigenic and physical properties ( Table 4) . Their expression levels appeared to be heightened by the presence of the mutants S46G, K465Q and S215P 32 as well as by mutations L95M, I221M and R429K. Importantly, all of these DS2-stabilized constructs maintained increased physical stability at 60 °C, which ranged from 6-to 7-fold for the A149C Y458C-based constructs to 13-to 19-fold for the N183GC N428C-based constructs ( Supplementary Fig. 2 and Supplementary Table 2) .
To provide insight into the increased expression associated with the S46G, K465Q and S215P mutants, we determined and solved the structure of the DS2 immunogen sc9-10 A149C Y458C S46G K465Q S215P E92D (Fig. 4c) at 2.92-Å resolution (Table 3) . Notably, none of the crystallographically visualized alterations, S46G, E92D, S215P and K465Q, resulted in changes in backbone movements greater than 1 Å (Fig. 4c) . We examined the local structure (Fig. 4c) of the mutants S46G, E92D and K465Q and observed that several of these mutations decreased the unfavorable interactions with proximal residues: S46 directly points toward another hydroxyl, E92 clashes with N254 (which hydrogen-bonds to D92), and K465 clashes electrostatically with a neighboring lysine. Moreover, as noted previously 32 , S215P destabilizes the formation of an elongated helix found in the RSV postfusion-F form.
To assess the effects of these mutations on the immunogenicity of these DS2 immunogens, we immunized CB6F1/J mice (Fig. 4d) . Notably, four of the DS2-stabilized RSV F trimers showed 2.5-to 4-fold-increased elicitation of RSV-neutralizing responses relative to DS-Cav1. All of the increased titers involved variants with the triple mutant S46G, K465Q and S215P in the A2 strain. RSV F variants from the CH18537 and Long RSV strains containing these or other mutations also showed both homologous and heterologous neutralization titers ( Supplementary Fig. 4 ). To understand factors that related to immunogenicity, we again used statistical analyses, incorporating information from cycles 1-4 (Fig. 4e) . Similarly to the analyses using data from cycles 1-3, both quaternary-specific-antibody affinity (P < 0.0001) and physical stability (P < 0.0001) significantly correlated with immunogenicity (Fig. 4e) , thus again suggesting that appropriate quaternary organization and improved physical stability can result in increased elicitation of RSV-neutralizing antibodies.
To provide additional insight into factors that might improve immunogenicity, we assessed sera reactivity to DS-Cav1 as well as to D25, AM14, motavizumab and MPE8 antigenic sites from select immunization groups across design cycles 1 to 4 (Supplementary Fig. 5 ). Antibody Left, Spearman correlation of antigenic and physical properties with neutralization titers for variants from design cycles 1 and 2 (including DS-Cav1) (n = 9 data points, two tailed). *P (Bonferroni corrected) <0.05. Right, correlation of quaternary-specific-antibody antigenicity with neutralization titer. 10,000 was used for antigenicity with no binding (NB) values. npg a r t i c l e s competition for binding by antibodies D25, AM14, motavizumab and MPE8 decreased the sera reactivity to prefusion stabilized F by at least two-thirds, thereby suggesting that much of the response was either site-Ø directed or quaternary specific. Overall, sera reactivity agreed well with immunogenicity, and the more stabilized DS2 immunogens elicited increased sera reactivity to DS-Cav1 as well as to the antigenic sites recognized by antibodies D25, AM14, motavizumab and MPE8.
DISCUSSION
By using iterative cycles of structure-based vaccine design, we identified second-generation DS2 F-glycoprotein immunogens with interprotomer disulfides that induced neutralizing activity approximately four-fold higher than that of DS-Cav1 after two immunizations of RSVnaïve CB6F1/J mice. We previously observed that titers in these mice and in rhesus macaques are correlated (r = 0.9975, P = 0.0451) 31 and therefore expect DS2 immunogens to also have increased immunogenicity in primates. Whether the immunogenicity of these DS2 immunogens is sufficient to induce titers in pregnant women beyond the critical 64-fold protective threshold needed to protect infants during the first 6 months after birth, however, will need to be answered through clinical trials. Furthermore, we note that maternal immunization may require only high magnitude, not durability, during the final weeks of gestation, and in the case of neutralizing activity, more is better.
The improved immunogenicity of the DS2 RSV F immunogens is thus likely to extend the duration and to increase the protection from RSV for infants in the context of maternal immunization.
We were surprised by the substantial increase in immunogenicity of sc9-10 versus sc9 (Fig. 2e) , given that they differed by only two amino acids, and we therefore sought to further characterize the difference between these two immunogens. Small-angle X-ray scattering characterization of sc9 and sc9-10 yielded distinct scattering patterns (Supplementary Fig. 6a ). The Kratky plots (Supplementary Fig. 6b ) showed that at high scattering-vector (q), sc9-10 converged to near zero, as expected for a compact molecule. In contrast, the sc9 Kratky plot plateaued near its maximum, a result consistent with a substantially flexible or unfolded molecule 42 . The estimated Porod exponents (Px) for sc9 and sc9-10 were 4.0 and 2.1, respectively ( Supplementary  Fig. 6c) ; these values were also consistent with sc9-10 being compact and sc9 occupying a larger volume 43 . Altogether, these data indicate substantial conformational flexibility of sc9, which was not apparent in the sc9 crystal structure, thus suggesting that solution characterization may be more appropriate for analyses of flexibility.
Although the second-generation DS2 RSV F immunogens, relative to DS-Cav1, showed significant increases in stability at higher temperature, other single-chain variants were less stable at physical extremes of pH and osmolality. Notably, the correlation between physical Supplementary Fig. 1c) . MW, molecular weight. Left, Spearman correlation of antigenic and physical properties with neutralization titers for design cycle 1, 2 and 3 variants (including DS-Cav1) (n = 10 data points, two tailed). *P (Bonferroni corrected) <0.05. Right, correlation of quaternary-specific-antibody antigenicity and physical stability with neutralization titer. Constructs containing a mutation at residue 183 were not included in the correlation for quaternaryspecific-antibody antigenicity because N183 is part of the AM14 epitope. 10,000 was used for antigenicity with NB values. npg a r t i c l e s stability and increased elicitation of RSV-protective responses was significant only when variants with interprotomer disulfides were included (Figs. 3e and 4e) . The increased stability of interprotomer disulfide-stabilized immunogens probably results from the inhibition of conformational rearrangements required to transition to the postfusion state. Moreover, different unfolding pathways may be inhibited by each interprotomer disulfide, because each showed characteristic increases in stability (approximately five-fold for A149C Y458C and ~20-fold for N183GC N428C) ( Table 2 , Supplementary Fig. 2 and Supplementary Table 2) . It remains to be seen whether combinations of interprotomer disulfides can be expressed and whether these might be further increased in stability. In this study, we used phosphatebuffered saline as a nominal formulation; when we increased salt concentrations to the 350 nM NaCl used in our previously published Titers from mice immunized with designs based on sc9-10 DS-Cav1 A149C Y458C are shown with half-filled circles; designs based on sc-9-10 DS-Cav1 N183GC N428C are shown with orange squares; and designs based on sc9-10 DS-Cav1 Q98C Q361C are shown with orange triangles. The final two designs were based on the RSV CH18537 and Long strains. Sera titers from 39 mice immunized with RSV F DS-Cav1 (gray symbols) are shown for reference. ****P <0.0001; **P <0.01; *P <0.05 by two-tailed Mann-Whitney tests. (e) Statistical analysis of design cycles 1-4. Left, Spearman correlation of antigenic and physical properties with neutralization titers for variants from design cycles 1-4 (including DS-Cav1) (n = 16 data points, two tailed). *P (Bonferroni corrected) <0.05. Right, correlation of quaternary-specific-antibody antigenicity (n = 15 data points) and physical stability (n = 16 data points) with neutralization titer. Constructs containing mutations at residue 183 were not included in the correlation for quaternary-specific-antibody antigenicity because N183 is part of the AM14 epitope. 10,000 was used for antigenicity with NB values. a r t i c l e s stability assessments 31 , the second-generation immunogens showed greater tolerance of physical extremes ( Table 2 ). In addition, we were concerned by the extensive loss of activity resulting from ten freezethaw cycles, but we found that the freeze-thaw damage could be limited by the introduction of 10% glycerol (Supplementary Table 3) . Although in vivo data on RSV F stability is not available, the introduction of the DS mutation in the viral context also results in increased immunogenicity 44 . The link between increased stability of pre-F and increased immunogenicity thus appears to be applicable to both protein-subunit and live-attenuated-vaccine contexts 44 .
designs for residues mutated to cysteine to form interprotomer disulfides (mutations labeled and in stick representation). (b) Engineered singlechain RSV F glycoproteins with interprotomer disulfides, assessed by SDS-PAGE (uncropped gel in
We previously tested 16 disulfide variants, including A149C Y458C, and three variants of N183C during our first-generation stabilization of mature RSV F, but all of these failed to express 31 . This failure may relate to structural rearrangements of prefusion RSV F between mature and immature states. Specifically, mature pre-F buries the C terminus of F 2 and the N terminus of F 1 , both of which must be exposed in immature pre-F (the trimeric uncleaved F 0 ), because furin must have access to these sites to perform the cleavage required for F activation. If interprotomer disulfides were incompatible with trimeric uncleaved F 0 , then their formation (and expression) might require folding directly into the mature prefusion state, as we appear to the achieved with the sc9-10 version of DS-Cav1. Although interprotomer disulfides do form with influenza A hemagglutinin 45 the hemagglutinin trimer does not show the extensive prefusion structural rearrangements of fusion machines from either RSV or HIV-1 (refs. 31,46) .
Could the iterative structure-based optimization described here have utility in the improvement of other vaccine immunogens? In a previous study, we have shown how structure-based design can be used to stabilize the prefusion closed conformation of HIV-1 (ref. 46); it should be possible to stabilize the prefusion forms of other type 1 fusion proteins, including those from paramyxovirus pathogens 47 , such as human metapneumovirus 48 and parainfluenza virus 49 . Whether the iterative optimization described here can be applied to other fusion proteins will probably depend on the relationship between the prefusion stability of these other fusion glycoproteins and their immunogenicity.
In creating a matrix of information 31, 50 by which to improve immunogenicity, we used measurements of not only immunogenicity but also antigenic and physical properties. To these, we added a design dimension, which allowed us to sample the information matrix so that statistical analyses of experimental observations could identify a direction by which to improve RSV-protective responses. In the four cycles described here, structure provided a means to both design variants and to understand their properties. Overall, we believe that, in the same way that structure-based drug design has allowed for the iterative optimization of lead therapeutic compounds (as in ref. 51) , the informatics of design, properties, structure and immunogenicity described here to achieve DS2 RSV F immunogens should allow for the iterative optimization of other lead vaccine antigens.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes.
Coordinates and structure factors have been deposited in the Protein Data Bank under accession codes PDB 5K6B (sc9 DS-Cav1), PDB 5K6C (sc9-10 DS-Cav1), PDB 5K6F (sc9-19 DS-Cav1), PDB 5K6G (sc9-24 DS-Cav1), PDB 5K6H (sc9-10 DS-Cav1 A149C Y458C) and PDB 5K6I (sc9-10 DS-Cav1 A149C Y458C S46G E92D S215P K465Q). 
npg ONLINE METHODS
Protein expression and purification. RSV F mutations were generated by sitedirected mutagenesis with the Stratagene QuikChange procedure. RSV F variants were expressed by transient transfection of Expi293F cells with 293Fectin (Invitrogen). Cell-culture supernatants were harvested 5 d after transfection and centrifuged at 10,000g to remove cell debris. The supernatants were sterile filtered, and RSV F proteins were purified by nickel and streptactin-affinity chromatography followed by size-exclusion chromatography. The final yield was calculated on the basis of at least two purification runs. The nickel and streptactin purification tags were removed for animal immunization and crystallization studies. To remove the purification tags, proteins were digested with 2 U/mg restriction-grade thrombin (Novagen) overnight at 4 °C and then purified by a second round of size-exclusion chromatography in PBS buffer. The Expi293F cells were authenticated at the source. Mycoplasma testing was performed through Hoechst DNA staining.
Screening of prefusion-stabilized RSV F constructs. Prefusion RSV F variants were derived from the RSV F (+) foldon construct, which consists of RSV F residues 1-513 with a C-terminal T4 fibritin trimerization motif (foldon), thrombin site, His 6 -tag, and Strep-tag II or the modified RSV F DS-Cav1 construct 31 . A 96-well-microplate transient-gene-expression approach was used to achieve high-throughput expression of various RSV F proteins, as described previously 52 . Briefly, 24 h before transfection, HEK 293T cells were seeded in each well of a 96-well-microplate at a density of 2.5 × 10 5 cells/ml in expression medium (high-glucose DMEM supplemented with 10% ultra-low IgG FBS and 1× nonessential amino acids) and incubated at 37 °C, 5% CO 2 for 20 h. Plasmid DNA and TrueFect-Max (United BioSystems) were mixed and added to the growing cells, and the 96-well plate was incubated at 37 °C, 5% CO 2 . One day after transfection, enriched medium (high glucose DMEM plus 25% ultra-low IgG FBS, 2× nonessential amino acids and 1× glutamine) was added to each well, and the 96-well plate was returned to an incubator for continuous culture. On day five after transfection, supernatants with the expressed RSV F variants were harvested and tested by ELISA for binding to D25, AM22, 5C4 and motavizumab antibodies with Ni 2+ -NTA microplates. After incubation of the harvested supernatants at 4 °C for 1 week, ELISAs were repeated. The HEK 293T cells were authenticated at the source. Mycoplasma testing was performed through Hoechst DNA staining.
RSV F antigenic characterization.
A fortéBio Octet Red384 instrument was used to measure binding kinetics of RSV F variants to antibodies targeting the prefusion form 5, 19, 27, 29, 53 . All assays were performed with agitation set to 1,000 r.p.m. in phosphate-buffered saline (PBS) supplemented with 1% bovine serum albumin (BSA) to minimize nonspecific interactions. The final volume for all solutions was 50 µl/well. Assays were performed at 30 °C in tilted black 384-well plates (Geiger Bio-One). Ni-NTA sensor tips (fortéBio) were used to load histidine-tagged proteins for 300 s to allow capture. Biosensor tips were then equilibrated for 90 s in PBS with 1% BSA before measurement of association with antigen-binding fragments (Fabs) in solution (0.007 µM to 0.5 µM) for 300 s; Fabs were then allowed to dissociate for 300-1,200 s depending on the observed dissociation rate. Parallel correction to subtract systematic baseline drift was carried out by subtraction of the measurements recorded for a loaded sensor incubated in PBS and 1% BSA. Data analysis and curve fitting were carried out with Octet software, version 8.0. Experimental data were fitted with the binding equations describing a 1:1 interaction. Global analyses of the data sets assuming reversible binding (full dissociation) were carried out with nonlinear least-squares fitting, allowing a single set of binding parameters to be obtained simultaneously for at least four concentrations used in each experiment.
Physical stability of RSV F variants. To assess the physical stability of the prefusion conformation of designed RSV F glycoproteins under various stress conditions, we treated the proteins at a concentration of 50 µg/ml with a variety of pharmaceutically relevant stresses such as extreme pH, high temperature, low and high osmolality, and repeated freeze-thaw cycles. The physical stability of treated RSV F variants was evaluated by the preservation of antigenic site Ø after treatment, as assessed by the site-Ø-specific antibody D25. In pH treatments, the RSV F glycoprotein solution was adjusted to pH 3.5 and pH 10 through exchange with appropriate buffers and was incubated at room temperature for 60 min and subsequently neutralized to pH 7.4. Temperature treatments were carried out by incubation of the RSV F glycoprotein solutions at 50 °C and 70 °C for 60 min in a PCR cycler with heated lid. In osmolality treatments, RSV F glycoprotein solutions originally containing 137 mM NaCl in PBS buffer were either diluted with 2.5 mM Tris buffer, pH 7.5, to an osmolality of 10 mM NaCl or adjusted with 4.5 M MgCl 2 to a final concentration of 3.0 M MgCl 2 . Protein solutions were incubated for 60 min at room temperature and then returned to PBS buffer and concentrated to 50 µg/ml. The freeze-thaw treatment was carried out through ten cycles of freezing of RSV F glycoprotein solutions in liquid nitrogen and thawing at 37 °C. The ten cycles of freeze-thaw treatment were also used to assess some RSV F variants that were supplemented with 5% or 10% glycerol. All RSV F glycoproteins were diluted to 50 µg/ml with PBS buffer, and their ability to bind D25 Fab was measured with an Octet instrument with the protocol described above. Each measurement was carried out at least twice. The degree of physical stability is reported as the ratio of the steady-state D25-binding level before and after stress treatment.
Negative-stain electron microscopy. Samples were adsorbed to freshly glowdischarged carbon-film grids, rinsed twice with buffer and stained with freshly made 0.75% uranyl formate. Images were recorded on an FEI T20 microscope with a 2,000 × 2,000 Eagle CCD camera at a pixel size of 1.5 Å. Image analysis and 2D averaging was performed with Bsoft 54 and EMAN 55 .
Dynamic light scattering.
A DynaPro Plate Reader II (Wyatt Technology) was used to perform DLS analysis at 830 nm to measure the approximate size and size distributions of RSV F immunogens. Protein samples were concentrated to 1 mg/ml in PBS and were centrifuged at 13,000 r.p.m. for 40 min at 4 °C immediately before analysis. Samples of 30 µl each were read in black clear-bottom 384-well plates (Corning 3540) at 25 °C, with ten data acquisitions per sample. Data were analyzed with Dynamics software v7.1.7 (Wyatt Technology).
Mouse immunizations.
All animal experiments were reviewed and approved by the Animal Care and Use Committee of the Vaccine Research Center, NIAID, NIH, under animal protocol 13-454, and all animals were housed and cared for in accordance with local, state, federal and institutional policies in an American Association for Accreditation of Laboratory Animal Care (AAALAC)-accredited facility at the NIH. Hybrid mice that were the first filial offspring of a cross between BALB/cJ females (C) and C57BL/6J males (B6) (Jackson Laboratory), known as CB6F1/J, at ages 6-12 weeks, were intramuscularly injected with RSV F immunogens at week 0 and week 3. At least ten mice were used per immunization group. Researchers carrying out the immunizations were blinded to the immunogens. All mice used in these studies were female, and there was no randomization of animals. With our previous immunization results with DS-Cav1 and Poly I:C 56 , which gave a neutralization geometric mean titer of 1,765 with an s.d. of 1,589, if for a novel immunogen, the sample size was ten, and the neutralization titer was ≥4,000 the statistical power was 99.4%. The frozen RSV F variant immunogen proteins were thawed on ice and mixed with five-fold (w/w) poly I:C (Invivogen) adjuvant (i.e., 10 µg RSV F and 50 µg Poly I:C per animal per immunization), and injections took place within 1 h of immunogen: adjuvant preparation. No adverse effects from immunization were observed. Blood was collected at least 3 d before immunization and at weeks two, five and seven after the initial immunization.
Viruses and cells. Viral stocks were prepared and maintained as previously described 57 . Recombinant mKate-RSV expressing prototypic subtype A (strain A2) or subtype B (strain CH18537) F genes and the Katushka fluorescent protein were constructed as previously reported 58 . HEp-2 cells were maintained in Eagle's minimal essential medium containing 10% FBS (10% EMEM), supplemented with glutamine, penicillin and streptomycin.
RSV neutralization assays. Sera were distributed as four-fold dilutions from 1:10 to 1:163,840, mixed with an equal volume of recombinant mKate-Respiratory syncytial virus expressing prototypic F genes from subtype A (strain A2) or subtype B (strain CH18537) and the Katushka fluorescent protein, and incubated at 37 °C for 1 h. Next, 50 µl of each serum dilution/virus mixture was added to HEp-2 cells, which had been seeded at a density of 2.4 × 10 4 in 30 µl minimal essential medium (MEM) in each well of 384-well black optical-bottom plates, npg and incubated for 20-22 h before spectrophotometric analysis at 588-nm excitation and 635-nm emission (SpectraMax Paradigm, Molecular Devices). The IC 50 for each sample was calculated by curve fitting and nonlinear regression with GraphPad Prism (GraphPad Software).
The protective threshold was calculated as follows: clinical administration of palivizumab (Synagis) at 15 mg/kg leads to patient sera levels at a trough of ~40 µg/ml. This serum concentration protects infants from severe disease and protects cotton rats from RSV infection. In the neutralization assay described above, 40 µg/ml of palivizumab yielded an EC 50 of 100.
Crystallization and X-ray data collection of prefusion-stabilized RSV F proteins. Crystals of RSV F single-chain RSV F prefusion variants were grown by the vapor-diffusion method in hanging drops at 20 °C by mixture of 1 µl of RSV F with 1 µl of reservoir solution 59 . Crystals of RSV F sc9 DS-Cav1 and sc9-24 DS-Cav1 grew in sodium acetate, pH 5.5, lithium sulfate, magnesium sulfate, PEG 400 conditions. Specifically, sc9 DS-Cav1 crystals grew in 0.1 M sodium acetate, pH 5. , 11% isopropanol and 17% (w/v) PEG 8000, and were transferred to a solution containing mother liquor supplemented with 30% glycerol before being cryocooled in liquid nitrogen. sc9-19 DS-Cav1 crystals grew in 0.1 M Na citrate, pH 5.6, 15% isopropanol and 17% (w/v) PEG 4000, and were transferred to mother liquor supplemented with 15% 2R-3R-butanediol before being stored in liquid nitrogen. sc9-10 DS-Cav1 A149C Y458C crystals grew in 0.1 M phosphate-citrate, pH 4.2, 0.12 M NaCl and 9.5% (w/v) PEG 8000, and were also transferred to mother liquor supplemented with 15% 2R-3R-butanediol before being stored in liquid nitrogen. The sc9-10 DS-Cav1 A149C Y458C S46G E92D S215P K465Q crystals grew in 0.1 M Na cacodylate, pH 6.5, 0.2 M ZnAc and 17% (w/v) PEG 8000, and were frozen in mother liquor supplemented with 22% ethylene glycol. All X-ray diffraction data were collected at a wavelength of 1.00 Å at SER-CAT beamline ID-22.
Structure determination, refinement and analysis of prefusion-stabilized RSV F. X-ray diffraction data were integrated and scaled with the HKL2000 suite 60 , and molecular-replacement solutions were obtained by PHASER 61 with the RSV F DS-Cav1 structure (PDB 4MMU 31 ) as a search model. Manual model building was carried out with COOT 62 , and refinement was performed in PHENIX 63 . The final data collection and refinement statistics are presented in Table 3 . Ramachandran plots indicated that for all structures >93% of residues were in the most favored regions, and <2% of residues were in disallowed regions. Antigenic site-Ø r.m.s. deviation calculations were based on residues 61-71 and 194-219, which were within 10 Å of the D25 antibody in the structure of the RSV F-D25 complex.
Correlation of immunogenicity with different properties. The correlations between immunogenicity and the following properties were measured with Spearman correlation: elution volume, expression yield, antigenicity toward site-Ø antibodies (geometric mean of D25, AM22 and 5C4 K d values), motavizumab (K d ), quaternary-specific antibodies (geometric mean of MPE8 and AM14 K d values), and physical stability (average D25 reactivity retained after exposure to seven different physical extremes). The correlation was considered significant if the adjusted P value based on Bonferroni correction was <0.05 (equivalent to P <0.05/6 = 0.00833).
Sera antigenic analysis. Mouse sera from a subset of immunization groups from the iterative optimization cycles were assessed for binding to RSV F DS-Cav1. Antigenic epitope targeting was assessed with a fortéBio Octet HTX instrument by competition with antigenic site-Ø antibody D25, quaternary-targeting antibodies MPE8 and AM14, as well as motavizumab. Sera from week 5 were diluted 1:300 in 1% BSA/PBS. Anti-pentahistidine (HIS1K) sensor tips obtained from fortéBio were equilibrated in PBS before the assays. RSV F DS-Cav1 trimeric protein at 20 µg/ml in 1% BSA/PBS was loaded onto HIS1K biosensors for 300 s. The sensor tips were subsequently equilibrated in 1% BSA/PBS for 60 s, and this was followed by capture of antibodies D25, AM14, MPE8 or Mota at 50 µg/ml for 300 s. HIS1K tips loaded with DS-Cav1 and D25, AM14, MPE8 or Mota were equilibrated for 180 s in 1% BSA/PBS, and this was followed by a serum association step for 300 s and a subsequent dissociation step for an additional 60 s. A parallel assay was performed in the absence of antibodies D25, AM14, Mota or MPE8 to determine the serum response in the absence of competing antibodies. The naive prebleed sera response for each group of immunogens was used as a reference. All experiments were performed in duplicate, and the average of the two data sets was analyzed with Octet and GraphPad Prism 6 software.
SEC-SAXS.
Data were collected on beamline 4-2 of the Stanford Synchrotron and Radiation Lightsource (SSRL) with a focused 11-keV X-ray beam to irradiate a thin-wall quartz-capillary cell placed 2.5 m upstream of a Rayonix MX 225HE detector, as described previously 64 . 50 µL of sc9 or sc9-10 (1 mg/mL) was injected onto a high-resolution Sepharose 200 column (GE Healthcare) with a flow rate of 50 µL/min in 20 mM Na 3 PO 4 , pH 7.4, 150 mM NaCl, 0.02% NaN 3 and 1 mM EDTA. Guinier fits, real-space transformation, estimation of Porod-Debye exponents and volume-of-correlation analyses were performed in ScÅtter (http:// www.bioisis.net/tutorial/). Measurements were repeated at least twice.
Figures. Structure figures were prepared with PyMOL (http://www.pymol.org/). Neutralization data and correlation figures were generated with GraphPad Prism (http://www.graphpad.com/scientific-software/prism/). Phylogenetic trees were generated with Mega6.
